Dec 01, 2014 8:00 am EST Heat Biologics, Inc. to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2 in New York
Oct 27, 2014 8:05 am EDT Heat Biologics, Inc. Commences Patient Dosing of Phase 2 Clinical Study of Vesigenurtacel-L for the Treatment of Bladder Cancer
Oct 02, 2014 7:35 am EDT Heat Biologics, Inc. Completes Enrollment of Phase 1 Clinical Trial of Vesigenurtacel-L for the Treatment of Bladder Cancer Required to Advance to Phase 2
Sep 30, 2014 7:30 am EDT Heat Biologics, Inc. to Present at the 13th Annual BIO Investor Forum in San Francisco on Tuesday, October 7, 2014
Sep 18, 2014 8:05 am EDT Heat Biologics Commences Patient Dosing in Phase 2 Study of Viagenpumatucel-L for the Treatment of Non-Small Cell Lung Cancer
Sep 04, 2014 7:30 am EDT Heat Biologics, Inc. to Present and Webcast at Two Investor Conferences in September
Aug 25, 2014 8:05 am EDT Heat Biologics, Inc. Closes on Up to $7.5 Million Secured Term Loan Facility
Aug 04, 2014 8:05 am EDT Heat Biologics Amends Bladder Cancer Protocol for Early Advancement Into Phase 2 Clinical Studies